Thermo Fisher Scientific (TMO)

How global shocks reach TMO

None of the tracked sector channels map to Thermo Fisher Scientific (Life Sciences Tools & Services), so only geography applies. Stories centered on the United States register as exposure, because the company is registered in the United States.

Direction is a tendency across cycles, not a forecast. Sector mapping uses the Finnhub industry classification; geography uses country of registration, not revenue by region.

What actually moves Thermo Fisher Scientific

Thermo Fisher's debt is large and mostly fixed, so the coupon is a slow channel. Borrowings at par were $39.46 billion, with $3.53 billion due within 12 months. The main floating piece is a euro note of about $1.18 billion tied to EURIBOR. Swaps cut interest expense. The live rate and credit channel is customer capital spending: pharma, biotech, universities and governments delay instruments before Thermo Fisher's own notes reprice.

Trade and China policy already moved a margin. Analytical Instruments segment margin fell, and the company attributes that mainly to tariffs, related currency effects, investments and mix. The filing expanded its tariff language and added Chinese rules that push local partnering and local suppliers, in a year when China sales declined. Asia-Pacific was 18% of revenue. Export licensing is on the filing's list, which is the chip-and-controls channel for instruments.

The less obvious shock is US federal funding, which the six themes barely name. Academic and government revenue fell in 2025. The filing ties some demand to budget appropriations and cites the October 2025 shutdown. A Washington funding gap can hit this business harder than an oil headline.

Drawn from the annual filing cited below. Not a forecast and not investment advice.

What Thermo Fisher Scientific sells and where it earns

Thermo Fisher sells lab instruments, consumables, diagnostics and services to pharmaceutical and biotech companies, universities, government agencies, hospitals and industrial customers. Revenue was $44.56 billion in 2025, up from $42.88 billion. It reports four segments. Laboratory Products and Biopharma Services is by far the largest at $23.98 billion. Life Sciences Solutions, where bioproduction drove growth, was $10.37 billion, Analytical Instruments $7.55 billion and Specialty Diagnostics $4.68 billion. The shares below use segment revenue before $2.03 billion of intersegment eliminations. By customer location, North America was $23.03 billion, or 52%, Europe 27%, Asia-Pacific 18% and other regions 4% (101% after rounding). The United States alone was $22.24 billion, about half. The filing does not size China, but says sales there declined in 2025 while other regions grew, and that academic and government revenue fell on customer hesitancy in the US and macro conditions in China. In 2025 it bought the filtration and separation business of Solventum, and it has agreed to buy Clario, which provides endpoint data for clinical trials, for about $8.875 billion in cash.

Customer concentration

The 10-K does not report any customer at 10% or more of revenue. It describes a broad base of pharma and biotech companies, labs, universities, healthcare providers, government agencies and research institutions, and says demand from some of them "depends on capital spending policies of our customers and on government funding policies."

Debt

Thermo Fisher had $39.46 billion of borrowings at par at December 31, 2025, up from $31.33 billion, with $3.53 billion of short-term obligations and current maturities due within 12 months. Nearly all of it is fixed-rate senior notes in dollars, euros, Swiss francs and yen; the main floating piece is a $1.18 billion EURIBOR-based euro note due 2027. Interest rate and cross-currency swaps cut 2025 interest expense by about $283 million.

Risk factors that moved this year

• Federal funding risk is sharper. The filing ties spending by some customers to budget allocations and timely passage of the federal budget, and newly cites the October 2025 government shutdown, warning that a similar impasse could delay or reduce federal spending. Academic and government revenue already declined in 2025.
• China localization is a new item. The international risks now include Chinese regulations that require partnering with local companies and give government-backed customers incentives to buy from local suppliers, at a time when Thermo Fisher's China sales were falling.
• Tariff language expanded to cover volatility from changing tariff policies and countermeasures. Analytical Instruments segment margin fell to 23.0% from 26.2%, which the company attributes mainly to tariffs and related currency effects, strategic investments and business mix.

How this changes the exposure read

Thermo Fisher looks like a healthcare name, but its most direct shocks are policy shocks. US academic and government funding is the clearest: the filing ties demand to federal budgets and cites the October 2025 shutdown, which the six shock types do not capture well. Trade/tariff risk and China tension arrive together, through tariffs that cut Analytical Instruments margin and Chinese rules favoring local suppliers. Chip/export rules matter through the export licensing requirements the filing lists. Rates/Fed act through $39.46 billion of mostly fixed-rate debt and customers' capital spending. Credit stress shows up as weaker biotech budgets. Oil shocks are minor.

Source: Thermo Fisher 10-K, FY2025. Checked 2026-10-07. Figures are from the filing and may differ from the live stats above.

What is moving it now

Key stats

Recent filings

Related tickers